AAAAAA

   
Results: 1-25 | 26-30 |
Results: 26-30/30
SELECTING APPROPRIATE ANTIHYPERTENSIVE DRUG DOSAGES
Authors: JOHNSTON GD
Citation: Gd. Johnston, SELECTING APPROPRIATE ANTIHYPERTENSIVE DRUG DOSAGES, Drugs, 47(4), 1994, pp. 567-575
MARKET PENETRATION OF NEW DRUGS IN ONE UNITED-KINGDOM REGION - IMPLICATIONS FOR GENERAL-PRACTITIONERS AND ADMINISTRATORS
Authors: MCGAVOCK H WEBB CH JOHNSTON GD MILLIGAN E
Citation: H. Mcgavock et al., MARKET PENETRATION OF NEW DRUGS IN ONE UNITED-KINGDOM REGION - IMPLICATIONS FOR GENERAL-PRACTITIONERS AND ADMINISTRATORS, BMJ. British medical journal, 307(6912), 1993, pp. 1118-1120
SLEEP-RELATED HYPOXEMIA IN HYPERTENSIVE AND NORMOTENSIVE MEN
Authors: GLEADHILL IC MCCRUM EE PATTERSON CC JOHNSTON GD EVANS A MACMAHON J
Citation: Ic. Gleadhill et al., SLEEP-RELATED HYPOXEMIA IN HYPERTENSIVE AND NORMOTENSIVE MEN, Thorax, 48(5), 1993, pp. 534-536
SINGLE-DRUG THERAPY FOR HYPERTENSION IN MEN
Authors: JOHNSTON GD
Citation: Gd. Johnston, SINGLE-DRUG THERAPY FOR HYPERTENSION IN MEN, The New England journal of medicine, 329(14), 1993, pp. 1043-1044
EFFECTS OF PRAVASTATIN IN PATIENTS WITH SERUM TOTAL CHOLESTEROL LEVELS FROM 5.2 TO 7.8 MMOL LITER (200 TO 300 MG DL) PLUS 2 ADDITIONAL ATHEROSCLEROTIC RISK-FACTORS
Authors: BEHOUNEK BD MARKOWITZ JS BERGMAN M MCGOVERN ME KASSLERTAUB KB VANHANEN H ELORANTA M JUVONEN J KANTOLA I KEKKI S KIVELA H KNUTAR F NISSEN M SALMI J SALONEN R TARPILA S TUNTURIHIHNALA H AMANN FW BERENDES G BONNER G DUBACH UC EGGSTEIN M FRANKENBERG HV FROER KL HOHL H HOPPE F KUMMER H MARZ W MOCCETTI T NOSEDA G REUTTER FW SCHWENKE R VOSSCHULTE G WAMBACH G WEIDMANN P BONNIER JJRM DEWEERD P HUIGE MC JANSEN LJ TERIJDT AJ TEVELDE K OLSSON AG LARSSON H ASPLUND J DAHLQVIST A LONNQVIST F FRITHZ G HOGLUND C KJELLSTROM T KUYLENSTIERNA J MOLLER B OSTERGREN J CRAMB R DAVIES J",IVERSON,"JOHNSTON GD MUNRO A PEACOCK I RITCHIE LD RITTER J RYLANCE PB SEVER PS SIMMONS RL
Citation: Bd. Behounek et al., EFFECTS OF PRAVASTATIN IN PATIENTS WITH SERUM TOTAL CHOLESTEROL LEVELS FROM 5.2 TO 7.8 MMOL LITER (200 TO 300 MG DL) PLUS 2 ADDITIONAL ATHEROSCLEROTIC RISK-FACTORS, The American journal of cardiology, 72(14), 1993, pp. 1031-1037
Risultati: 1-25 | 26-30 |